Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2001-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1046/J.0306-5251.2001.01499.XPMID 11678778PMCID PMC2014584
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population.

  2003cited by this paper
• Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

  2001cited by this paper
• Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes.

  2000cited by this paper
• Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication.

  2000cited by this paper
• CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates.

  2000cited by this paper
• Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole

  1999cited by this paper
• Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects.

  1999cited by this paper
• Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.

  1999cited by this paper
• Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.

  1999cited by this paper
• Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

  1999cited by this paper
• Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E‐3174

  1999cited by this paper
• Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects

  1999cited by this paper
• High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands.

  1999cited by this paper
• A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin.

  1999cited by this paper
• Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

  1999cited by this paper
• Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate.

  1998cited by this paper
• An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians.

  1998cited by this paper
• A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.

  1998cited by this paper
• Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.

  1998cited by this paper
• Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer

  1998cited by this paper
• CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans.

  1998cited by this paper
• Genetic association between sensitivity to warfarin and expression of CYP2C9*3.

  1997cited by this paper
• Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments.

  1997cited by this paper
• The hydroxylation of omeprazole correlates with S-mephenytoin and proguanil metabolism

  1997cited by this paper
• Metabolic disposition of lansoprazole in relation to the S‐mephenytoin 4′‐hydroxylation phenotype status

  1997cited by this paper
• Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S‐mephenytoin 4′‐hydroxylation phenotype and genotype *

  1997cited by this paper
• The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase.

  1997cited by this paper
• Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele.

  1997cited by this paper
• No correlation between side-chain of propranolol oxidation and S-mephenytoin 4'-hydroxylase activity.

  1997cited by this paper
• Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy

  1997cited by this paper
• The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

  1996cited by this paper
• The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype.

  1996cited by this paper
• Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro

  1996cited by this paper
• Genetic analysis of the cytochrome P‐450IIC18 (CYP2C18) gene and a novel member of the CYP2C subfamily

  1996cited by this paper
• Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S‐mephenytoin oxidation in Tanzanians

  1996cited by this paper
• Identification of a new non-functional CYP2C18 allele in Japanese: substitution of T204 to A in exon2 generates a premature stop codon.

  1996cited by this paper
• The hydroxylation of omeprazole correlates with S‐mephenytoin metabolism: A population study

  1995cited by this paper
• Geographical/Interracial Differences in Polymorphic Drug Oxidation

  1995cited by this paper
• Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S‐mephenytoin 4′‐hydroxylation status

  1995cited by this paper
• Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.

  1995cited by this paper
• Single‐dose kinetics of clomipramine: Relationship to the sparteine and S‐mephenytoin oxidation polymorphisms

  1994cited by this paper
• Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects.

  1994cited by this paper
• Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.

  1994cited by this paper
• The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.

  1994cited by this paper
• Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8.

  1994cited by this paper
• In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase.

  1994cited by this paper
• Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.

  1994cited by this paper
• Biochemistry and molecular biology of the human CYP2C subfamily.

  1994cited by this paper
• Pharmacokinetics of Citalopram in Relation to the Sparteine and the Mephenytoin Oxidation Polymorphisms

  1993cited by this paper
• Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.

  1993cited by this paper
• Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans

  1992cited by this paper
• Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects.

  1992cited by this paper
• Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.

  1992cited by this paper
• The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study.

  1991cited by this paper
• The mephenytoin oxidation polymorphism is partially responsible for the N‐demethylation of imipramine

  1991cited by this paper
• A screening test for slow metabolisers of tolbutamide.

  1991cited by this paper
• Genetic polymorphism of S-mephenytoin hydroxylation.

  1989cited by this paper
• The gastric H+,K+-ATPase: the site of action of omeprazole.

  1989cited by this paper
• Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities

  1989cited by this paper
• cDNA and amino acid sequences of two members of the human P450IIC gene subfamily.

  1987cited by this paper
• Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin.

  1986cited by this paper
• Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation

  1985cited by this paper
• Complete nucleotide sequence of a methylcholanthrene-inducible cytochrome P-450 (P-450d) gene in the rat.

  1985cited by this paper
• Pharmacogenetics of Tolbutamide Metabolism in Humans

  1978cited by this paper

• The Association Between Promoter Tandem Repeat Polymorphism (pVNTR) and CYP2C9 Gene Expression in Human Liver Samples

  2025cites this paper
• Untargeted metabolomics and transcriptomics joint analysis of the effects of polystyrene nanoplastics on lipid metabolism in the mouse liver

  2025cites this paper
• A Comparison of Molecular Techniques for Improving the Methodology in the Laboratory of Pharmacogenetics

  2024cites this paper
• Current and Future Perspectives on the Management of Helicobacter pylori: A Narrative Review

  2024cites this paper
• Upregulation of ACSL, ND75, Vha26 and sesB genes by antiepileptic drugs resulted in genotoxicity in drosophila.

  2024cites this paper
• Zang Siwei Qingfei Mixture Alleviates Pulmonary Arterial Hypertension in Rats: Integrated Network Pharmacology and Metabolomics

  2024cites this paper
• A network meta-analysis: evaluating the efficacy and safety of concurrent proton pump inhibitors and clopidogrel therapy in post-PCI patients

  2024cites this paper
• Potential of pharmacogenetics in minimizing drug therapy problems in cystic fibrosis.

  2024cites this paper
• The Diversity of CYP2C19 Polymorphisms in the Thai Population: Implications for Precision Medicine

  2024cites this paper
• Implementing pharmacogenetic testing to optimize proton-pump inhibitors use among Indian population based on CPIC-CYP2C19-PPI dosing guidelines: The need of the hour

  2024cites this paper
• Novel Cytochrome P450 2C119 Enzymes in Cynomolgus and Rhesus Macaques Metabolize Progesterone, Diclofenac, and Omeprazole

  2023cites this paper
• Novel Cytochrome P450 2C94 Functionally Metabolizes Diclofenac and Omeprazole in Dogs

  2023cites this paper
• Novel Approaches to Characterize Individual Drug Metabolism and Advance Precision Medicine

  2023cites this paper
• Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database

  2023cites this paper
• An Overview on Adverse Drug Reactions (ADR) And Its Biomarkers

  2023cites this paper
• Metabolism of testosterone and progesterone by cytochrome P450 2C19 allelic variants

  2023cites this paper
• Effects of CYP2C19 inhibitors on mavacamten pharmacokinetics in rats based on UPLC-MS/MS.

  2023cites this paper
• CYP2C19 Polymorphism in Ischemic Heart Disease Patients Taking Clopidogrel After Percutaneous Coronary Intervention in Egypt

  2023cites this paper
• Identification of cytochrome P450 2C18 and 2C76 in tree shrews: P450 2C18 effectively oxidizes typical human P450 2C9/2C19 chiral substrates warfarin and omeprazole with less stereoselectivity.

  2023cites this paper
• A comprehensive analysis of six forms of cytochrome P450 2C (CYP2C) in pigs

  2022cites this paper
• CYP2C9 gen polimorfizmlerinin losartan kullanan hipertansif hastalarda tedavi yanıtı üzerine etkisi

  2022cites this paper
• Mouse Cyp2c expression and zonation structure in the liver begins in the early neonatal stage

  2022cites this paper
• Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults

  2022cites this paper
• Pharmacogenomics of lipid-lowering agents: the impact on efficacy and safety.

  2022cites this paper
• Assessment of metabolic activation of felbamate in chimeric mice with humanized liver in combination with in vitro metabolic assays.

  2022cites this paper
• Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44

  2022cites this paper
• Disparities in Alzheimer Disease and Mild Cognitive Impairment Among Native Hawaiians and Pacific Islanders

  2021cites this paper
• Sources of Interindividual Variability.

  2021cites this paper
• Identification and Enzymatic Activity Evaluation of a Novel CYP2C9 Allelic Variant Discovered in a Patient

  2021cites this paper
• Genotype Frequency of Cytochrome P450 2C9 (CYP2C9) Mutations in Iraqi Ethnic Groups

  2021cites this paper
• Prevalence of CYP2C19*2 carriers in Saudi ischemic stroke patients and the suitability of using genotyping to guide antiplatelet therapy in a university hospital setup

  2021cites this paper
• Polymorphisms in CYP2C8 gene in Pakistani population and their frequencies in various ethnic groups

  2021cites this paper
• Prevalence of CYP2C19*2 carriers in Saudi ischemic stroke patients and the suitability of using genotyping to guide antiplatelet therapy in a university hospital setup

  2021cites this paper
• New benzodiazepines in Europe – a review

  2021cites this paper
• In vitro enantioselective inhibition of the main human CYP450 enzymes involved in drug metabolism by the chiral pesticide tebuconazole.

  2021cites this paper
• Single Nucleotide Polymorphisms and Pharmacogenomics

  2021cites this paper
• Polymorphisms of genes related to phase-I metabolic enzymes affecting the clinical efficacy and safety of clopidogrel treatment

  2021cites this paper
• Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets

  2021cites this paper
• Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies

  2021cites this paper
• Optimized Administration of Voriconazole and Therapeutic Drug Monitoring in Children and Adolescents: A Single-Centre Retrospective Experience from China

  2021cites this paper
• Hepatic Cytochrome P450 Abundance and Activity in the Developing and Adult Göttingen Minipig: Pivotal Data for PBPK Modeling

  2021cites this paper
• Absence of ethnic difference on single‐dose pharmacokinetics of rivoceranib between healthy male Caucasian, Japanese, and Chinese subjects

  2020cites this paper
• Structure of Cytochrome P450 2C9*2 in Complex with Losartan: Insights into the Effect of Genetic Polymorphism

  2020cites this paper
• CYP Genotypes Are Associated with Toxicity and Survival in Osteosarcoma Patients

  2020cites this paper
• Polymyositis Presenting as Rhabdomyolysis After the Initiation of Omeprazole

  2020cites this paper
• Potential proton pump inhibitor–related adverse effects

  2020cites this paper
• CYP2C19 gene polymorphisms among Moroccan patients with breast cancer disease: A case-control study

  2020cites this paper
• Using in vitro methods to determine P450s responsible for metabolism and discrimination from other oxidative pathways

  2020cites this paper
• Comparative study of prophylaxis with high and low doses of voriconazole in children with malignancy

  2020cites this paper
• Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol

  2020cites this paper
• A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug–Drug–Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine

  2020cites this paper
• The Usefulness of Prasugrel as Rescue Medication in Neuroendovascular Therapy

  2020cites this paper
• Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: Bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment.

  2020cites this paper
• Brivaracetam (Briviact®)

  2019cites this paper
• Single-nucleotide polymorphism screening and RNA sequencing of key messenger RNAs associated with neonatal hypoxic-ischemia brain damage

  2019cites this paper
• Low-frequency variants at the CYP2C9 locus among Puerto Rican patients on warfarin: in silico predictions of functionality and conservation.

  2019cites this paper
• Brivaracetam (Briviact®)

  2019cites this paper
• Preliminary Experience of Preoperative Modification of Platelet Aggregation

  2019cites this paper
• Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV.

  2019cites this paper
• Animal models to study bile acid metabolism.

  2019cites this paper
• Biomarkers for Antiplatelet Therapy

  2019cites this paper
• Cytochrome P450 1A1, 2C9, 2C19, and 3A4 Polymorphisms Account for Interindividual Variability of Toxicological Drug Metabolism in Cynomolgus Macaques.

  2018cites this paper
• Different inhibitory effects of azole-containing drugs and pesticides on CYP2C9 polymorphic forms: An in vitro study.

  2018cites this paper
• Combination of CYP2C19 genotype with non-genetic factors evoking phenoconversion improves phenotype prediction

  2018cites this paper
• Intravenous Sedatives and Analgesics

  2018cites this paper
• Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug

  2018cites this paper
• Farmacogenética de reacciones adversas a fármacos antiepilépticos

  2018cites this paper
• Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia)

  2018cites this paper
• Current knowledge of microRNA-mediated regulation of drug metabolism in humans

  2018cites this paper
• Expression and Activity of CYP2C8 and 2C9 in Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

  2018influential citation
• The emergence of new psychoactive substance (NPS) benzodiazepines: A review.

  2018cites this paper
• The emergence of new psychoactive substance (NPS) benzodiazepines: A review.

  2018cites this paper
• Vonoprazan versus proton-pump inhibitors for gastric endoscopic submucosal dissection-induced ulcers: a systematic review and meta-analysis

  2018cites this paper
• Role of oxylipins in cardiovascular diseases

  2018cites this paper
• The Cytochrome P450 Slow Metabolizers CYP2C9*2 and CYP2C9*3 Directly Regulate Tumorigenesis via Reduced Epoxyeicosatrienoic Acid Production.

  2018cites this paper
• Clinical Pharmacokinetics and the Impact of Genetic Polymorphism on a CYP2C19 Substrate, BMS-823778, in Healthy Subjects

  2018cites this paper
• Characterization of CYP2C Induction in Cryopreserved Human Hepatocytes and Its Application in the Prediction of the Clinical Consequences of the Induction.

  2018cites this paper
• Canine and Feline Differences in the Cytochrome P450 Transcriptome and Drug Metabolism

  2018cites this paper
• Pharmacogenetics in Cardiovascular Medicine.

  2018cites this paper
• EFFECT OF GREEN TEA AND ITS BIOACTIVE COMPOUND, (-)-EPIGALLOCATECHIN-3-GALLATE, ON WEIGHT REDUCTION AND ON CYTOCHROME P450 NG MEI FONG FACULTY OF MEDICINE UNIVERSITY OF MALAYA

  2018cites this paper
• Metabolic Barrier of the Gastrointestinal Tract

  2018cites this paper
• Development of genotyping method for functionally relevant variants of cytochromes P450 in cynomolgus macaques.

  2018cites this paper
• Drug Metabolism in the Liver.

  2017cites this paper
• Développement de méthodes analytiques par LC-MS/MS pour la caractérisation de l’activité et de l’expression des CYP450s chez l’humain

  2017cites this paper
• Safety and Efficacy of Prasugrel with Endovascular Treatment for Unruptured Cerebral Aneurysm

  2017cites this paper
• Effects of obesity on liver cytochromes P450 in various animal models.

  2017cites this paper
• In vivo Phenotyping Methods: Cytochrome P450 Probes with Emphasis on the Cocktail Approach.

  2017cites this paper
• Concomitant use of proton pump inhibitors and dual antiplatelet therapy for cardiovascular outcomes.

  2017cites this paper
• In vitro CYP-mediated drug metabolism in the zebrafish (embryo) using human reference compounds.

  2017cites this paper
• Interspecies metabolic diversity of harmaline and harmine in in vitro 11 mammalian liver microsomes.

  2017cites this paper
• Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China

  2017cites this paper
• Pharmacodynamic and cytogenetic evaluation in CYP2C19*2 and CYP2C19*3 allelomorphism in South Indian population with clopidogrel therapy.

  2017cites this paper
• The combination of pharmacogenetic and pharmacokinetic analyses to optimize clomipramine dosing in major depression: a case report

  2017cites this paper
• Polymorphism of CYP 2 D 6 , CYP 2 C 19 , CYP 2 C 9 and CYP 2 C 8 in the Faroese population

  2017cites this paper
• Genetic Polymorphism of CYP2C9 Among Sistani Ethnic Group in Gorgan

  2017cites this paper
• Both canonical and noncanonical Wnt signalling may be required for detoxification following ETP class mycotoxin exposure.

  2017cites this paper
• Role of genetic polymorphism in nutritional supplementation therapy in personalized medicine.

  2017cites this paper
• Pharmacogenetics of Drug Metabolism

  2017cites this paper
• Evaluation of the VKORC 1 and CYP2C9 Gene Polymorphisms and Their Effects on the Emergency Complications in the Patients Using Warfarin

  2017cites this paper
• ABCC2 (1249G > A) polymorphism implicates altered transport activity for sorafenib

  2017cites this paper